Response could be better/higher among HLA-A*0201 positive patients when ipilimumab is combined with MDX-1379. Data from that 2nd line phase III will be presented at ASCO.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.